Zastosowanie pregabaliny u chorej z bólem neuropatycznym w przebiegu neuropatii obwodowej indukowanej chemioterapią – opis przypadku Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2022
Słowa kluczowe:
ból neuropatyczny, obwodowa neuropatia indukowana chemioterapią, pregabalina
##plugins.themes.bootstrap3.article.main##
Abstrakt
Neuropatia indukowana chemioterapią (CIPN, chemotherapy-induced peripheral neuropathy) to częste jatrogenne powikłanie i następstwo przyczynowego leczenia choroby nowotworowej. Ryzyko rozwoju CIPN zależy od rodzaju chemioterapii, całkowitej dawki, a także od czynników leżących po stronie pacjenta. Nie ma obecnie potwierdzonej metody, która mogłaby zapobiegać wystąpieniu CIPN. Ból neuropatyczny może występować u 40% chorych z CIPN, znacznie pogarsza jakość życia pacjenta i może być leczony jedynie objawowo, zarówno w formie farmakoterapii, jak i metodami niefarmakologicznymi. Rekomendowane są leki przeciwpadaczkowe, przeciwdepresyjne, analgetyki opioidowe oraz leki topikalne. Leki te udowodniły swoją skuteczność w populacji chorych z bólem neuropatycznym niezwiązanym z leczeniem nowotworu, ale nadal brak jest dobrych jakościowo badań oceniających ich skuteczność u pacjentów z CIPN. Dostępne w literaturze badania prowadzone w małych grupach chorych potwierdzają skuteczność leków przeciwpadaczkowych i przeciwdepresyjnych w tej grupie pacjentów, co obserwujemy również w praktyce klinicznej. W artykule przedstawiono przypadek chorej z silnym bólem neuropatycznym w przebiegu CIPN, skutecznie leczonej pregabaliną w połączeniu z duloksetyną.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kocot-Kępska , M. (2022). Zastosowanie pregabaliny u chorej z bólem neuropatycznym w przebiegu neuropatii obwodowej indukowanej chemioterapią – opis przypadku. Medycyna Faktów , 15(1(54), 94-100. https://doi.org/10.24292/01.MF.0122.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Burgess J, Ferdousi M, Gosal D et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncol Ther. 2021; 9(2): 385-450. http://doi.org/10.1007/s40487-021-00168-y.
2. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies – A growing problem for patients and health care providers. Brain Behav. 2016; 7: e00558.
3. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth. 2017; 119: 737-49.
4. Seretny M, Currie GL, Sena ES et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155: 2461-70.
5. Bennett MI, Rayment C, Hjermstad M et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012; 153(2): 359-65. http://doi.org/10.1016/j.pain.2011.10.028.
6. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013; 111: 105-11.
7. Jones D, Zhao F, Brell J et al. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015; 9: 1-10.
8. Boyette-Davis JA, Hou S, Abdi S et al. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018; 8: 363-75.
9. Ventzel L, Madsen CS, Karlsson P et al. Chronic pain and neuropathy following adjuvant chemotherapy. Pain Med. 2018; 19: 1813-24.
10. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention [Review]. Neuro Oncol. 2012; 14(suppl 4): iv45-54.
11. Mols F, van de Poll-Franse LV, Vreugdenhil G et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016; 69: 28-38.
12. Vincenzi B, Frezza AM, Schiavon G et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013; 21(5): 1313-9.
13. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941-67.
14. Zajączkowska R, Kocot-Kępska M, Leppert W et al. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019; 20(6): 1451. http://doi.org/10.3390/ijms20061451.
15. Przeklasa-Muszyńska A, Dobrogowski J, Kocot-Kępska M. Kliniczna ocena chorego z bólem. In: Dobrogowski J, Wordliczek J, Kocot-Kępska M (ed). Ból. Wiedza w kieszeni. Termedia Wydawnictwa Medyczne, Poznań 2020: 25-34.
16. ChPL Fludarabin-Ebewe, 25 mg/ml, koncentrat do sporządzania roztworu do wstrzykiwań lub infuzji.
17. Fallon M, Giusti R, Aielli F et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(suppl 4): iv166-iv191. http://doi.org/10.1093/annonc/mdy152.
18. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
19. Chincholkar M. Analgesic mechanisms of gabapentin and effects in experimental pain models: a narrative review. Br J Anaesth. 2018; 120: 1315-34.
20. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12: 44-56.
21. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018; 12(2): 108-17.
22. Aoki M, Kurauchi Y, Mori A et al. Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin induced cold and mechanical allodynia in rats. Biol Pharm Bull. 2014; 37: 322-6.
23. Peng P, Xi Q, Xia S et al. Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 586-90.
24. Ling B, Coudoré F, Decalonne L et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology. 2008; 55(5): 724-8. http://doi.org/10.1016/j.neuropharm.2008.06.007.
25. Saif MW, Syrigos K, Kaley K et al. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010; 30(7): 2927-33.
26. Nihei S, Sato J, Kashiwaba M et al. Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy. Gan To Kagaku Ryoho. 2013; 40: 1189-93.
27. Salehifar E, Janbabaei G, Hendouei N et al. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin Drug Investig. 2020; 40(3): 249-57. http://doi.org/10.1007/s40261-019-00882-6.
28. Avan R, Janbabaei G, Hendouei N et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane- induced sensory neuropathy: a randomized clinical trial. J Res Med Sci. 2018; 23: 52.
29. Sugimoto M, Takagi T, Suzuki R et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021; 21(1): 1319. http://doi.org/10.1186/s12885-021-09069-9.
30. Hincker A, Frey K, Rao L et al. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain. 2019; 160(8): 1835-46.
31. Derry S, Bell RF, Straube S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1: CD007076.
32. Charakterystyka produktu leczniczego: pregabalina.
33. Szczudlik A, Dobrogowski J, Wordliczek J et al. Diagnosis and management of neuropathic pain: Review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part one. Neurol Neurochir Pol. 2014; 48: 262-71.
34. Lussier D. Pain Pharmacotherapy in Older Patients. W: Pain 2016: Refresher Courses, 16th World Congress on Pain.
35. Markman JD, Jensen TS, Semel D et al. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017; 17(6): 718-28. http://doi.org/10.1111/papr.12516.
36. Dworkin RH, O`Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain; an overview and literature update. Mayo Clin Proc. 2010; 85(3 suppl): S3-S14.
37. Johnson P, Becker L, Halpern R et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013; 33(1): 35-44.
38. Holbech JV, Jung A, Jonsson T et al. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017; 10: 1467-75.
39. Arnold LM, McCarberg BH, Clair AG et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgrad Med. 2017; 129(8): 921-33. http://doi.org/10.1080/00325481.2017.1384691.
40. Song SY, Ko YB, Kim H et al. Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis. Medicine (Baltimore). 2020; 99(1): e18653. http://doi.org/10.1097/MD.0000000000018653.
2. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies – A growing problem for patients and health care providers. Brain Behav. 2016; 7: e00558.
3. Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth. 2017; 119: 737-49.
4. Seretny M, Currie GL, Sena ES et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014; 155: 2461-70.
5. Bennett MI, Rayment C, Hjermstad M et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012; 153(2): 359-65. http://doi.org/10.1016/j.pain.2011.10.028.
6. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013; 111: 105-11.
7. Jones D, Zhao F, Brell J et al. Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. J Cancer Surviv. 2015; 9: 1-10.
8. Boyette-Davis JA, Hou S, Abdi S et al. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018; 8: 363-75.
9. Ventzel L, Madsen CS, Karlsson P et al. Chronic pain and neuropathy following adjuvant chemotherapy. Pain Med. 2018; 19: 1813-24.
10. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention [Review]. Neuro Oncol. 2012; 14(suppl 4): iv45-54.
11. Mols F, van de Poll-Franse LV, Vreugdenhil G et al. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population. Eur J Cancer. 2016; 69: 28-38.
12. Vincenzi B, Frezza AM, Schiavon G et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013; 21(5): 1313-9.
13. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941-67.
14. Zajączkowska R, Kocot-Kępska M, Leppert W et al. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019; 20(6): 1451. http://doi.org/10.3390/ijms20061451.
15. Przeklasa-Muszyńska A, Dobrogowski J, Kocot-Kępska M. Kliniczna ocena chorego z bólem. In: Dobrogowski J, Wordliczek J, Kocot-Kępska M (ed). Ból. Wiedza w kieszeni. Termedia Wydawnictwa Medyczne, Poznań 2020: 25-34.
16. ChPL Fludarabin-Ebewe, 25 mg/ml, koncentrat do sporządzania roztworu do wstrzykiwań lub infuzji.
17. Fallon M, Giusti R, Aielli F et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(suppl 4): iv166-iv191. http://doi.org/10.1093/annonc/mdy152.
18. Finnerup NB, Attal N, Haroutounian S et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162-73. http://doi.org/10.1016/S1474-4422(14)70251-0.
19. Chincholkar M. Analgesic mechanisms of gabapentin and effects in experimental pain models: a narrative review. Br J Anaesth. 2018; 120: 1315-34.
20. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014; 12: 44-56.
21. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018; 12(2): 108-17.
22. Aoki M, Kurauchi Y, Mori A et al. Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin induced cold and mechanical allodynia in rats. Biol Pharm Bull. 2014; 37: 322-6.
23. Peng P, Xi Q, Xia S et al. Pregabalin attenuates docetaxel-induced neuropathy in rats. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 586-90.
24. Ling B, Coudoré F, Decalonne L et al. Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection. Neuropharmacology. 2008; 55(5): 724-8. http://doi.org/10.1016/j.neuropharm.2008.06.007.
25. Saif MW, Syrigos K, Kaley K et al. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010; 30(7): 2927-33.
26. Nihei S, Sato J, Kashiwaba M et al. Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy. Gan To Kagaku Ryoho. 2013; 40: 1189-93.
27. Salehifar E, Janbabaei G, Hendouei N et al. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin Drug Investig. 2020; 40(3): 249-57. http://doi.org/10.1007/s40261-019-00882-6.
28. Avan R, Janbabaei G, Hendouei N et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane- induced sensory neuropathy: a randomized clinical trial. J Res Med Sci. 2018; 23: 52.
29. Sugimoto M, Takagi T, Suzuki R et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021; 21(1): 1319. http://doi.org/10.1186/s12885-021-09069-9.
30. Hincker A, Frey K, Rao L et al. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. Pain. 2019; 160(8): 1835-46.
31. Derry S, Bell RF, Straube S et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1: CD007076.
32. Charakterystyka produktu leczniczego: pregabalina.
33. Szczudlik A, Dobrogowski J, Wordliczek J et al. Diagnosis and management of neuropathic pain: Review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part one. Neurol Neurochir Pol. 2014; 48: 262-71.
34. Lussier D. Pain Pharmacotherapy in Older Patients. W: Pain 2016: Refresher Courses, 16th World Congress on Pain.
35. Markman JD, Jensen TS, Semel D et al. Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials. Pain Pract. 2017; 17(6): 718-28. http://doi.org/10.1111/papr.12516.
36. Dworkin RH, O`Connor AB, Audette J et al. Recommendations for the pharmacological management of neuropathic pain; an overview and literature update. Mayo Clin Proc. 2010; 85(3 suppl): S3-S14.
37. Johnson P, Becker L, Halpern R et al. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013; 33(1): 35-44.
38. Holbech JV, Jung A, Jonsson T et al. Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process. J Pain Res. 2017; 10: 1467-75.
39. Arnold LM, McCarberg BH, Clair AG et al. Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgrad Med. 2017; 129(8): 921-33. http://doi.org/10.1080/00325481.2017.1384691.
40. Song SY, Ko YB, Kim H et al. Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis. Medicine (Baltimore). 2020; 99(1): e18653. http://doi.org/10.1097/MD.0000000000018653.